Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manoj Khatore

Cardiovascular Disease Oxnard, CA Medical Doctor

NPI 1528140639 CMS profile 295612

1901 Outlet Center Dr Ste 260, Oxnard, CA 93036

Open in the dashboard

General payments

$6,057

225 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manoj Khatore of Oxnard, CA is reported in the CMS Open Payments database as having received $6,057 across 225 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,031 43
2024 General $707 28
2023 General $1,137 43
2022 General $709 25
2021 General $467 18
2020 General $246 12
2019 General $1,761 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manoj Khatore
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Manoj Khatore were reported at $1,031. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Manoj Khatore Cardiovascular Disease median Middle half National median
2019 $1,761 $450 $127–$1,392 $163
2020 $246 $242 $77–$751 $114
2021 $467 $335 $101–$1,037 $132
2022 $709 $395 $121–$1,211 $149
2023 $1,137 $443 $136–$1,283 $160
2024 $707 $450 $136–$1,323 $164
2025 $1,031 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $799 29 payments
  2. Medtronic Vascular, Inc. $710 11 payments
  3. Abiomed $681 14 payments
  4. Novartis Pharmaceuticals Corporation $515 31 payments
  5. Actelion Pharmaceuticals US, Inc. $490 19 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $344 16 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $306 15 payments
  8. Amgen Inc. $303 13 payments
  9. Merck Sharp & Dohme Corporation $278 11 payments
  10. Esperion Therapeutics, Inc. $270 12 payments
  11. Other $1,362 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,309 210 payments
  2. Travel and Lodging $471 3 payments
  3. Education $277 12 payments
Products named General payments · program years 2019–2025
  1. VenaSeal $649 6 payments
  2. FARXIGA $639 24 payments
  3. Impella $367 7 payments
  4. VERQUVO $307 13 payments
  5. Repatha $289 12 payments
  6. UPTRAVI $288 11 payments
  7. ENTRESTO $280 12 payments
  8. NEXLETOL $270 12 payments
  9. OPSUMIT $223 9 payments
  10. LEQVIO $223 18 payments
  11. Other $2,698 110 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 109 drugs

Part D claims

8,698

Median for Cardiology: 2,533

Drug cost

$1,438,547

Median for Cardiology: $485,213

Branded share of claims

30%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 329 $313,237
Xarelto Rivaroxaban Brand 215 $255,004
Jardiance Empagliflozin Brand 201 $211,147
Farxiga Dapagliflozin Propanediol Brand 129 $115,599
Entresto Sacubitril/Valsartan Brand 78 $92,294
Verquvo Vericiguat Brand 45 $65,138
Ozempic Semaglutide Brand 47 $60,425
Inpefa Sotagliflozin Brand 45 $46,465
Brilinta Ticagrelor Brand 34 $27,448
Repatha Syringe Evolocumab Brand 23 $21,957

The 10 drugs with the highest cost, of 109 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$1,189,573

Of which drugs: $296

Medicare patients

904

Average age 78

Services billed

19,937

513 women, 391 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 63%
Diabetes 56%
Arthritis 47%
Heart failure 42%
Chronic kidney disease 36%
Atrial fibrillation 32%
Depression 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 11 44 $296

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $188
$188 129 —
VYNDAQEL
  • PFIZER INC. $147
$147 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $35
$35 215 —
Wegovy
  • Novo Nordisk Inc $32
$32 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $30
$30 201 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

225 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record